The HD treatment seems to better modulate the expression of neuroprotective and pro-survival molecules, as Bcl-xL and BDNF, through a fine modulation of SIRT1 and the HDACs class I, as confirmed by the higher number of rescued MNs, the delayed disease onset and increased lifespan found in treated mice compared to controls. The gene discussed is BCL2L1; the disease is Huntington disease.